Saliva-based Detection of CD44

Inclusion Criteria: * Patient has the ability to understand and the willingness to sign a written informed consent. * Previously untreated, measurable squamous cell carcinoma of the oral cavity or oropharynx with no evidence of distant metastasis, T1-4N0-3M0 * No prior history of treated upper aerodigestive tract cancer * No concurrent, second, active malignancy other than oral cavity and/or oropharynx cancer * Planned to undergo treatment with curative intent * Able to follow up after therapy at 3, 6, 12, and 18 months after completion of therapy during routine post treatment follow up * For control subjects: no evidence or history of upper aerodigestive tract cancer * For control subjects: absence of any suspected or confirmed active malignancy at time of enrollment * Patients may have had prior therapy for malignancy other than upper aerodigestive malignancy completed 2 years prior to enrollment if they have been disease free since completion of therapy * Patient is ≥ 18 years of age. * Both men and women of all races and ethnic groups are eligible for this trial. * Performance Status ≤ ECOG 3 * Patient is able to gargle and spit 5 cc of saline * Patients may be concurrently enrolled in other therapeutic or detection clinical trials Exclusion Criteria: * Prior completed therapy for an upper aerodigestive tract cancer within the past 3 years. * Patient unable to gargle and spit 5 cc of saline, or anticipated to be unable to gargle and spit after completion of therapy * Patient unable or does not intend to undergo curative therapy * Patient with concurrent, second primary malignancy under active therapy or completed therapy within 2 years prior to enrollment.